Understanding Factors that Limit Access to Opioid Use Disorder Treatment in the Hospital to Inform Innovative Approaches to Expand Hospital-Based Treatment
了解限制在医院接受阿片类药物使用障碍治疗的因素,为扩大医院治疗的创新方法提供信息
基本信息
- 批准号:10379944
- 负责人:
- 金额:$ 18.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionBeliefBuprenorphineCaringCommunitiesConsultCountryCountyDataDevelopmentDevelopment PlansDisease ManagementEffectivenessElectronic Health RecordEnsureEvidence based practiceEvidence based treatmentFocus GroupsFutureGoalsHealth PersonnelHealth ServicesHospitalistsHospitalizationHospitalsImprove AccessIncentivesInpatientsInterventionInterviewInvestigationKnowledgeLeadershipLearningLinkLiteratureMeasuresMedicalMentorsMentorshipMethodsModelingNaloxoneNational Institute of Drug AbuseNursesOverdoseOverdose reversalPatient CarePatientsPersonsPharmaceutical PreparationsPharmacistsPharmacy facilityPhysiciansPositioning AttributePrivatizationProcessProtocols documentationProviderPsychiatristPublicationsQualitative ResearchReach Effectiveness Adoption Implementation and MaintenanceRecoveryReportingResearchResearch MethodologyResearch PersonnelResearch Project GrantsScreening procedureService delivery modelSocial WorkersSpecialistState HospitalsStructureSuboxoneSurveysTestingTrainingUnited StatesUniversitiesaddictionbasecareercareer developmentcomparative effectiveness trialcostdissemination scienceevidence baseexperiencehigh riskimplementation barriersimplementation interventionimplementation scienceimprovedinnovationmedical specialtiesmeetingsmulti-component interventionnovel strategiesopioid epidemicopioid useopioid use disorderovertreatmentpilot testpost interventionprovider behaviorsafety netskillssubstance usetherapy developmentwaiverworkforce needs
项目摘要
PROJECT ABSTRACT With the career goal of becoming an independent health services researcher, Dr.
Susan Calcaterra describes a mentored research project and a rigorous career development plan which will
prepare her to become a leader in the integration of opioid use disorder (OUD) treatment in the hospital setting
with linkage to OUD care post discharge. Nearly 200 people died every day from an overdose in 2017 in the
United States (US). In 2012, there were 527,000 hospitalizations due to opioid use which cost more than $15
billion in medical care. For patients with OUD, there are proven benefits to initiating buprenorphine in the
hospital with treatment referrals and prescribing naloxone at discharge. Unfortunately, OUDs are often not
addressed in the hospital resulting in a missed opportunity to provide patients evidence-based treatment.
There are 50,000 hospital-based physicians (hospitalists) caring for hospitalized patients in the US. This vast
workforce offers a potential solution to initiate buprenorphine in the hospital, provide naloxone at discharge,
and ensure patients are referred to ongoing OUD treatment. There is a critical need to determine why
buprenorphine and naloxone are not routinely prescribed to hospitalized patients with OUD and to sustainably
integrate evidence-based OUD treatment in the hospital using the existing workforce. Without this knowledge,
many hospitalized patients will fail to receive lifesaving medication. The proposed research centers on the
hypothesis that hospitalist’s knowledge and beliefs impact OUD treatment and the hospital’s current structures
and processes do not support OUD treatment. Study Aims include: 1) a qualitative investigation into key
barriers to the integration of evidence-based OUD care into hospital practice in three academic hospitals with
hospitalists, psychiatrists, pharmacists, social workers and nurses; 2) the development of a multicomponent
intervention that adapts evidence-based OUD treatment to the hospital setting by addressing reported barriers
in Aim 1 and by systematically meeting the needs of hospitalists, nurses, pharmacists and social workers
within their workflow; and 3) pilot test a multicomponent intervention to improve OUD treatment in one hospital
over 12 months. Use the RE-AIM framework to measure changes in buprenorphine and naloxone prescribing
(Reach) and changes in the number of providers licensed to prescribe buprenorphine (Adoption) pre/post
intervention implementation. Interview hospital providers to identify ongoing Implementation barriers and to
learn about adaptations made to the intervention to improve its efficiency and ease of use. To accomplish
these aims, Dr. Calcaterra will pursue training in 1) qualitative research methods to inform the intervention
development, 2) intervention development to modify healthcare provider behaviors, and 3) dissemination and
implementation science for future intervention dissemination. Upon completion of these activities, along with
intensive mentorship, Dr. Calcaterra will be positioned to conduct a larger comparative effectiveness trial to
further implement, test and refine the intervention’s fidelity (future R01).
随着职业目标成为一个独立的卫生服务研究员,博士。
苏珊·卡尔卡特拉(Susan Calcaterra)描述了一个指导研究项目和严格的职业发展计划,该计划将
准备她成为阿片类药物使用障碍(OUD)治疗在医院环境整合的领导者
与出院后的OUD护理有关。2017年,每天有近200人死于过量用药。
United States(US). 2012年,有527,000人因使用阿片类药物而住院,费用超过15美元
亿元医疗保健。对于OUD患者,已证实在治疗期间开始丁丙诺啡治疗的益处
医院治疗转诊和处方纳洛酮出院。不幸的是,OUD通常不是
在医院解决,导致错过了为患者提供循证治疗的机会。
在美国,有50,000名医院医生(住院医师)照顾住院患者。这片广袤
劳动力提供了一个潜在的解决方案,在医院开始丁丙诺啡,在出院时提供纳洛酮,
并确保患者接受持续的OUD治疗。迫切需要确定为什么
丁丙诺啡和纳洛酮不是OUD住院患者的常规处方,
利用现有劳动力在医院整合循证OUD治疗。如果没有这些知识,
许多住院病人得不到救命的药物。拟议的研究中心在
假设住院医师的知识和信念影响OUD治疗和医院的现有结构
并且工艺不支持OUD处理。研究目的包括:(1)对关键问题进行定性研究。
在三所学术医院中,将循证OUD护理纳入医院实践的障碍,
医院医生、精神科医生、药剂师、社会工作者和护士; 2)发展一个多成分的
通过解决报告的障碍,使循证OUD治疗适应医院环境的干预措施
通过系统地满足住院医生、护士、药剂师和社会工作者的需求,
在他们的工作流程中;和3)在一家医院试点测试多组分干预以改善OUD治疗
超过12个月使用RE-AIM框架测量丁丙诺啡和纳洛酮处方的变化
(覆盖范围)和获得丁丙诺啡处方许可的提供者数量的变化(收养)
干预实施。与医院供应商进行访谈,以确定持续的实施障碍,
了解对干预措施进行的调整,以提高其效率和易用性。完成
为了实现这些目标,Calcaterra博士将继续接受定性研究方法的培训,为干预提供信息
发展,2)干预发展,以改变医疗保健提供者的行为,和3)传播和
未来干预传播的实施科学。这些活动完成后,沿着
在密集的指导下,Calcaterra博士将进行更大规模的比较有效性试验,
进一步实施、测试和完善干预的保真度(未来R 01)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susan L Calcaterra其他文献
Susan L Calcaterra的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susan L Calcaterra', 18)}}的其他基金
Understanding Factors that Limit Access to Opioid Use Disorder Treatment in the Hospital to Inform Innovative Approaches to Expand Hospital-Based Treatment
了解限制在医院接受阿片类药物使用障碍治疗的因素,为扩大医院治疗的创新方法提供信息
- 批准号:
10597051 - 财政年份:2020
- 资助金额:
$ 18.9万 - 项目类别:
相似海外基金
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Standard Grant